5456 completed, 2405 unknown, 2257 recruiting, 1448 terminated. 5770 Phase 2, 2976 Phase 1, 2034 Not applicable, 1394 Phase 3, 225 Phase 4.
Follow Carcinoma: new trials by email Literature Review of Carcinoma trials Research Report on Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma 9-ING-41, Carboplatin - Salivary Gland Carcinoma, Adenoid Cystic Carcinoma | Phase 2 | Withdrawn | Actuate Therapeutics Inc. | 2030-12-18 | 2022-02-22 | |
| STAGE-MTC Trial Thyroid Lobectomy With Ipsilateral Central Neck Dissection Biospecimen Collection, FDG-Positron Emission Tomography and Computed Tomography Scan, Ga-68 PET/CT Scan - Thyroid Gland Medullary Carcinoma | Not applicable | Not yet recruiting | Jonsson Comprehensive Cancer Center | 100 | 2027-09-02 | 2026-10-19 |
| Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome Shuganhuazhuo Formula, Targeted therapy, Immunotherapy - HCC - Hepatocellular Carcinoma, Chinese Herbal Medicine | Phase 2 | Not yet recruiting | Xiang-Qian | 120 | 2027-09-01 | 2026-08-27 |
| Removing the Planning Tumor Volume From Radiation Therapy for the Treatment of Head and Neck Squamous Cell Carcinoma Chemotherapy, Computed Tomography, Endoscopic Procedure - Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Not applicable | Not yet recruiting | City of Hope Medical Center | 30 | 2027-06-22 | 2026-11-09 |
| Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab PANDA-VAC, Pembrolizumab - Squamous Cell Lung Cancer, Squamous Non-small Cell Lung Cancer | Phase 1 | Suspended | UNC Lineberger Comprehensive Cancer Center | 6 | 2027-05-20 | 2026-04-23 |
| Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial Balstilimab, Biospecimen Collection, Botensilimab - Clear Cell Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 16 | 2027-05-17 | 2026-10-21 |
| Enfortumab Vedotin for the Treatment of Unresectable or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer, or NUT Carcinoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Differentiated Thyroid Gland Carcinoma, Metastatic NUT Carcinoma | Phase 2 | Not yet recruiting | Northwestern University | 56 | 2027-05-05 | 2026-10-07 |
| Chemo-embolization for Head and Neck Cancer Cisplatin - SCCHN, Squamous Cell Carcinoma | Phase 2 | Withdrawn | University of Alabama at Birmingham | 2027-05-01 | 2025-04-27 | |
| Lifileucel (TIL) Therapy After PD-1 Blockade Failure in Kidney Cancer Cyclophosphamide, Fludarabine, Aldesleukin (IL-2) - Kidney Cancers, Renal Cell Carcinoma (Kidney Cancer) | Phase 2 | Not yet recruiting | Beth Israel Deaconess Medical Center | 10 | 2027-04-26 | 2026-11-09 |
| Estimating The Rate Of Complete Ablation (A0) With The Use Of Biomechanical Deformable Image Registration RayAblation - Liver Tumors | Not applicable | Not yet recruiting | M.D. Anderson Cancer Center | 200 | 2027-04-01 | 2026-10-16 |
| Outcomes for IR and High Risk (HR) Non-muscle Invasive Bladder Cancer (NMIBC) and ctDNA-based Biomarkers for Response and Recurrence in Muscle Invasive Bladder Cancer (MIBC) This is a non-interventional, observational, prospective study. - NMIBC, MIBC | Not yet recruiting | Bladder Cancer Advocacy Network | 1400 | 2027-03-01 | 2026-10-26 | |
| A Clinical Study Evaluating the Safety and Efficacy of Ivonescimab as Second-line Treatment in Patients With Advanced Hepatocellular Carcinoma Ivonescimab - Hepatocellular Carcinoma (HCC), HCC - Hepatocellular Carcinoma | Phase 2 | Not yet recruiting | MedSIR | 44 | 2027-03-01 | 2026-11-04 |
| Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma Biospecimen Collection, Camonsertib, Computed Tomography - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 39 | 2027-02-13 | 2026-10-29 |
| Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell Carcinoma Biospecimen Collection, Bone Scan, Computed Tomography - Non-Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8 | Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 400 | 2027-02-10 | 2026-07-08 |
| A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck Cemiplimab, Fianlimab, Carboplatin - Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | University of Chicago | 90 | 2027-02-07 | 2026-01-20 |
| STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL) Ivonescimab - Adrenocortical Carcinoma, Pheochromocytoma | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 20 | 2027-02-07 | 2026-09-18 |
| SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma Stereotactic Body Radiation Therapy (SBRT), Anlotinib, Bemarituzumab - Locally Advanced or Metastatic Renal Cell Carcinoma | Phase 2 | Not yet recruiting | Fujian Cancer Hospital | 27 | 2027-02-01 | 2026-10-01 |
| Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer losartan, Paclitaxel - Platinum Resistant Ovarian Cancer | Phase 2 | Not yet recruiting | Massachusetts General Hospital | 27 | 2027-02-01 | 2026-09-22 |
| A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer NDV-01 (sustained-release gemcitabine-docetaxel) - Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) | Phase 3 | Not yet recruiting | Relmada Therapeutics, Inc. | 393 | 2027-02-01 | 2026-09-02 |
| A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma ONO-4578, Placebo, Nivolumab - Gastric Cancer, Esophagogastric Junction Cancer | Phase 3 | Not yet recruiting | Ono Pharmaceutical Co., Ltd. | 600 | 2027-02-01 | 2026-09-14 |
Showing 20 of 14002. Sign in to see all of them.
Carcinoma, Hepatocellular (3382) · Carcinoma, Renal Cell (1963) · Squamous Cell Carcinoma of Head and Neck (1958) · Carcinoma, Non-Small-Cell Lung (1103) · Head and Neck Neoplasms (856) · Neoplasms (850) · Breast Neoplasms (794) · Carcinoma, Ovarian Epithelial (786) · Cholangiocarcinoma (780) · Ovarian Neoplasms (772) · Nasopharyngeal Carcinoma (651) · Carcinoma, Squamous Cell (627) · Esophageal Squamous Cell Carcinoma (625) · Carcinoma, Transitional Cell (621)
Neoplasms, Glandular and Epithelial (13952) · Neoplasms by Histologic Type (13951) · Neoplasms (13152) · Neoplasms by Site (12156) · Adenocarcinoma (7634) · Digestive System Diseases (5320) · Digestive System Neoplasms (5222) · Urogenital Diseases (3851) · Urogenital Neoplasms (3733) · Female Urogenital Diseases and Pregnancy Complications (3679) · Female Urogenital Diseases (3665) · Liver Diseases (3430) · Head and Neck Neoplasms (3003) · Liver Neoplasms (2854)
Cisplatin (916) · pembrolizumab (659) · Carboplatin (516) · Radiotherapy (504) · Paclitaxel (490) · Gemcitabine (488) · Nivolumab (405) · Fluorouracil (382) · Bevacizumab (373) · Sorafenib (337) · Docetaxel (332) · Cetuximab (260) · lenvatinib (254) · Oxaliplatin (218) · Capecitabine (215)
National Cancer Institute (NCI) (515) · Sun Yat-sen University (429) · M.D. Anderson Cancer Center (245) · Memorial Sloan Kettering Cancer Center (174) · Fudan University (172) · Pfizer (136) · Novartis Pharmaceuticals (113) · Mayo Clinic (105) · Shanghai Zhongshan Hospital (93) · Seoul National University Hospital (91) · University Health Network, Toronto (91) · National Taiwan University Hospital (89) · AstraZeneca (84) · Bayer (77) · Merck Sharp & Dohme LLC (77)
United States (5894) · China (3210) · France (1198) · Canada (884) · Italy (880) · Spain (819) · South Korea (805) · United Kingdom (786) · Germany (754) · Taiwan (641) · Australia (525) · Netherlands (473) · Belgium (472) · Japan (428) · Poland (335)
Ming Shi, MD (23)
PMID 37146227, PMID 40812353, PMID 37185961, PMID 30207593, PMID 31150573, PMID 33538338, PMID 12049862, PMID 25057165, PMID 27238653, PMID 28410911, PMID 29433850, PMID 11981766, PMID 20375404, PMID 12540794, PMID 18650514, PMID 19097774, PMID 19192962, PMID 25577718, PMID 36897458, PMID 37407274, PMID 19095497, PMID 22551107, PMID 25712310, PMID 29628281, PMID 29875066, PMID 31401903, PMID 32402160, PMID 33526329, PMID 34143971, PMID 36852452, PMID 12091661, PMID 16757203, PMID 21374666, PMID 27240885, PMID 27686945, PMID 27932229, PMID 28837405, PMID 29471013, PMID 29584545, PMID 32499241, PMID 32557715, PMID 32716739, PMID 33058158, PMID 33300372, PMID 34341578, PMID 34795131, PMID 34905388, PMID 36410913, PMID 36990609, PMID 37097003
2023 (107), 2018 (70), 2016 (65), 2019 (65), U10CA032102 (59), 2017 (57), 2025 (49), P30CA033572 (47), 2014 (46), 2015 (46), P30CA043703 (42), P30CA016672 (41), P30CA015083 (36), U10CA031946 (33), U10CA180868 (31)